To view this email as a web page, click here.
 
In this issue of Dermatology Times, we focus on business issues affecting the practice: The latest on compounding pharmacies, operating in the cloud and more.
 
Dermatology Times cover
FDA moves to regulate medicines produced in bulk
The U.S. Food and Drug Administration issued a draft guidance in March proposing to regulate medicines that are produced in bulk by compounding pharmacies. Plus, in "Opposition to looming compounding practice changes," Dr. Murad Alam, M.D., president elect of the American Society for Dermatologic Surgery, addresses how changes in federal and state regulations that govern compounding medications could impact physicians and patients.
 
The business of dermatology
In this column, Dr. Ron Wheeland addresses the value of business knowledge among physicians. "It goes without saying that medical students and residents receive invaluable training that prepares them to provide high-quality care to their patients. For the vast majority of physicians the quality of medical education training they receive is not accompanied by a similar level of business training," he writes.
 
Healthcare in the cloud
Today, medical practices are considering cloud services for everything from revenue cycle management to patient engagement tools. HIMSS Analytics reports the number of healthcare provider organizations planning to use the cloud for back office functions has jumped from 22-46% within two years.
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.